Carlsbad, United States
Armonica Technologies, Inc., an innovative early-stage medtech company founded in 2017, is positioned at the intersection of Biotechnology and Information Technology. Operating out of the United States, the company champions its proprietary long-read DNA sequencing technology for precision medicine applications.
With the succinct slogan, "The Future of Epigenetic Sequencing for Precision Medicine," Armonica addresses limitations inherent in today’s genome sequencing methods, which demand extensive library preparation and confront significant computational challenges. The company's groundbreaking technique leverages nanochannels to guide single DNA molecules through nanopores for optical readout via Raman spectroscopy, promising to revolutionize genomic analysis, making it faster and more accurate.
Armonica's potential is underscored by its recent $2.00M Grant investment from the National Human Genome Research Institute on 31 August 2022, signaling strong confidence in its cutting-edge approach.
